Latest Period
Q4 2025
Security Snapshot
Senti Biosciences, Inc. - Common Stock, par value $0.0001 per share (SNTI) Institutional Ownership
CUSIP: 81726A209
13F Institutional Holders and Ownership History from Q3 2024 to Q4 2025
Institutions Reporting
15
Shares (Excl. Options)
5,614,365
Price
$1.04
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.
- Type / Class
- Equity / Common Stock, par value $0.0001 per share
- Symbol
- SNTI on Nasdaq
- Shares outstanding
- 34,471,650
- Price per share
- $0.77
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 5,614,365
- Total reported value
- $5,838,757
- % of total 13F portfolios
- 0%
- Share change
- -30,787
- Value change
- -$78,561
- Number of holders
- 15
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- SNTI - Senti Biosciences, Inc. - Common Stock, par value $0.0001 per share is tracked under CUSIP 81726A209.
- 15 institutions reported positions in Q4 2025.
- 6 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 15 to 15 between Q3 2025 and Q4 2025.
- Reported value moved from $7,909,282 to $5,838,757.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 15 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 81726A209?
CUSIP 81726A209 identifies SNTI - Senti Biosciences, Inc. - Common Stock, par value $0.0001 per share in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 81726A209:
Significant Owners of Senti Biosciences, Inc. - Common Stock, par value $0.0001 per share (SNTI) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Celadon Partners SPV 24 | 45% | 0% | $14,186,888 | +$112,225 | 13,511,322 | +0.8% | Celadon Partners SPV 24 | 19 Jan 2026 |
| BAYER HEALTHCARE LLC | 18% | $4,729,993 | 6,142,848 | Bayer HealthCare LLC | 27 Mar 2026 | |||
| New Enterprise Associates 15, L.P. | 14% | $11,968,700 | 3,775,615 | New Enterprise Associates 15, L.P. | 06 Mar 2025 | |||
| Nantahala Capital Management, LLC | 8.1% | -19% | $7,037,400 | +$5,422,973 | 2,220,000 | +336% | Nantahala Capital Management, LLC | 31 Mar 2025 |
| ARMISTICE CAPITAL, LLC | 5% | -50% | $4,564,204 | +$2,865,052 | 1,439,812 | +169% | Armistice Capital, LLC | 31 Mar 2025 |
| Nantahala Capital Partners Limited Partnership | 1.9% | -67% | $1,592,925 | +$637,170 | 502,500 | +67% | NANTAHALA CAPITAL PARTNERS LIMITED PARTNERSHIP | 31 Mar 2025 |
As of 31 Dec 2025, 15 institutional investors reported holding 5,614,365 shares of Senti Biosciences, Inc. - Common Stock, par value $0.0001 per share (SNTI). This represents 16% of the company’s total 34,471,650 outstanding shares.
Top 19 Institutional Shareholders
The largest institutional shareholders of Senti Biosciences, Inc. - Common Stock, par value $0.0001 per share (SNTI) together control 16% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| NEA Management Company, LLC | 11% | 3,775,615 | 0% | 0.2% | $3,926,640 |
| Nantahala Capital Management, LLC | 2.6% | 888,000 | 0% | 0.06% | $923,520 |
| VANGUARD GROUP INC | 1.8% | 628,697 | +2% | 0% | $653,845 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.42% | 144,797 | -5.3% | 0% | $150,594 |
| Virtu Financial LLC | 0.13% | 44,409 | 0% | $46,000 | |
| JANE STREET GROUP, LLC | 0.11% | 38,427 | 0% | $39,964 | |
| MSOP GP, L.L.C. | 0.1% | 35,737 | 0% | 0.01% | $37,166 |
| BlackRock, Inc. | 0.07% | 23,384 | +3.5% | 0% | $24,319 |
| NORTHERN TRUST CORP | 0.05% | 16,778 | +2.9% | 0% | $17,449 |
| STATE STREET CORP | 0.03% | 10,010 | 0% | 0% | $10,410 |
| UBS Group AG | 0.01% | 4,529 | 0% | $4,710 | |
| Tower Research Capital LLC (TRC) | 0.01% | 3,411 | +97% | 0% | $3,547 |
| SBI Securities Co., Ltd. | 0% | 336 | 0% | 0% | $349 |
| MORGAN STANLEY | 0% | 160 | 0% | 0% | $166 |
| BANK OF AMERICA CORP /DE/ | 0% | 75 | -83% | 0% | $78 |
| XTX Topco Ltd | 0% | 0 | -100% | $0 | |
| CITADEL ADVISORS LLC | 0% | 0 | -100% | $0 | |
| CITIGROUP INC | 0% | 0 | -100% | $0 | |
| TWO SIGMA INVESTMENTS, LP | 0% | 0 | -100% | $0 |
Institutional Holders of Senti Biosciences, Inc. - Common Stock, par value $0.0001 per share (SNTI) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 5,614,365 | $5,838,757 | -$78,561 | $1.04 | 15 |
| 2025 Q3 | 5,609,415 | $7,909,282 | -$2,933,848 | $1.41 | 15 |
| 2025 Q2 | 6,484,682 | $13,682,488 | +$1,724,635 | $2.11 | 14 |
| 2025 Q1 | 5,663,433 | $19,029,155 | +$16,777,530 | $3.36 | 14 |
| 2024 Q4 | 667,184 | $2,341,958 | -$330,207 | $3.51 | 14 |
| 2024 Q3 | 763,984 | $1,726,485 | +$1,717,436 | $2.26 | 12 |